These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 9346370)
41. Erythropoietin, an update, and where to in the future? Sulková S EDTNA ERCA J; 1998; 24(3):30-2, 35. PubMed ID: 10392076 [TBL] [Abstract][Full Text] [Related]
42. [Anaemia, cardiac failure and erythropoietin]. Cohen Solal A; Beauvais F Arch Mal Coeur Vaiss; 2005 Oct; 98(10):997-1001. PubMed ID: 16294546 [TBL] [Abstract][Full Text] [Related]
43. The biology of erythropoietin. Goldwasser E Blood Purif; 1991; 9(3):119-22. PubMed ID: 1666292 [No Abstract] [Full Text] [Related]
44. [Erythropoietin: indications and measurement]. Klein E; Georges A; Brossaud J; Bosredon Kd; Bordenave L; Corcuff JB Ann Biol Clin (Paris); 2009; 67(5):505-15. PubMed ID: 19789122 [TBL] [Abstract][Full Text] [Related]
45. [Erythropoietin as a protective agent in myocardial ischemia]. Schwartzenberg S; Keren G; George J Harefuah; 2006 May; 145(5):380-3, 396. PubMed ID: 16805223 [TBL] [Abstract][Full Text] [Related]
46. [Non erythropoietic effects of Erythropoietin]. Guglielmo C; Cantarelli C; Angeletti A; Todeschini P; Cravedi P G Ital Nefrol; 2019 Sep; 36(5):. PubMed ID: 31580542 [TBL] [Abstract][Full Text] [Related]
47. Update on erythropoietin. Fried W; Morley C Int J Artif Organs; 1985 Mar; 8(2):79-82. PubMed ID: 3886559 [No Abstract] [Full Text] [Related]
48. [What are the aims and targets of renal anemia therapy?]. Eckardt KU Dtsch Med Wochenschr; 2007 Sep; 132(36):1837-41. PubMed ID: 17726657 [No Abstract] [Full Text] [Related]
49. Erythropoietin: issues in its use as a therapeutic for the anemia of chronic renal failure. Eschbach JW; Adamson JW Blood Purif; 1990; 8(5):239-54. PubMed ID: 2091684 [No Abstract] [Full Text] [Related]
50. Erythropoietin resistance in the treatment of the anemia of chronic renal failure. Priyadarshi A; Shapiro JI Semin Dial; 2006; 19(4):273-8. PubMed ID: 16893403 [TBL] [Abstract][Full Text] [Related]
51. Choice of erythropoiesis stimulating agent in ESRD. Fishbane S; Shah HH Nephrol News Issues; 2013 Jun; 27(7):Supp 10-2. PubMed ID: 23855143 [No Abstract] [Full Text] [Related]
52. Erythropoietin: its role in the regulation of erythropoiesis and as a therapeutic in humans. Adamson JW Biotechnology; 1991; 19():351-63. PubMed ID: 1786475 [TBL] [Abstract][Full Text] [Related]
53. [Clinical use of erythropoietin]. Franchini M; Gandini G; Lippi G; De Gironcoli M; Cantini M; Aprili G Recenti Prog Med; 2004 Mar; 95(3):129-36; quiz 185. PubMed ID: 15143948 [TBL] [Abstract][Full Text] [Related]
54. Erythropoietin in cardiac disease: new features of an old drug. Ruifrok WP; de Boer RA; Westenbrink BD; van Veldhuisen DJ; van Gilst WH Eur J Pharmacol; 2008 May; 585(2-3):270-7. PubMed ID: 18407263 [TBL] [Abstract][Full Text] [Related]
55. Cellular protection by erythropoietin: new therapeutic implications? Joyeux-Faure M J Pharmacol Exp Ther; 2007 Dec; 323(3):759-62. PubMed ID: 17717190 [TBL] [Abstract][Full Text] [Related]
56. Managing anemia. What do we do now? Views from Canada. Mendelssohn DC; Muirhead N; Manns BJ Nephrol News Issues; 2007 Jun; 21(7):55-7. PubMed ID: 17623988 [No Abstract] [Full Text] [Related]
57. An unusual etiology of erythropoietin resistance: hyperthyroidism. Kaynar K; Ozkan G; Erem C; Gul S; Yilmaz M; Sonmez B; Ozdemir F; Ulusoy S Ren Fail; 2007; 29(6):759-61. PubMed ID: 17763175 [TBL] [Abstract][Full Text] [Related]
58. Erythropoietin in cancer: the new face of an old friend. Megalakaki C J BUON; 2008; 13(1):7-16. PubMed ID: 18404780 [TBL] [Abstract][Full Text] [Related]